Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boston Scientific invests in Intelect, gets DBS rights

Executive Summary

Boston Scientific has received a co-exclusive license to neuromodulation company Intelect Medical's Dimension software technology. Along with fellow Series B investor Greatbatch, Boston Scientific has also agreed to buy $11-13.5mm in Intelect common stock, and the two companies may buy additional equity in the future. (This financing for Intelect is considered a Series B extension.)
Deal Industry
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies